» Articles » PMID: 21984449

Quantifying Differences in Hepatic Uptake of the Liver Specific Contrast Agents Gd-EOB-DTPA and Gd-BOPTA: a Pilot Study

Overview
Journal Eur Radiol
Specialty Radiology
Date 2011 Oct 11
PMID 21984449
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To develop and evaluate a procedure for quantifying the hepatocyte-specific uptake of Gd-BOPTA and Gd-EOB-DTPA using dynamic contrast-enhanced (DCE) MRI.

Methods: Ten healthy volunteers were prospectively recruited and 21 patients with suspected hepatobiliary disease were retrospectively evaluated. All subjects were examined with DCE-MRI using 0.025 mmol/kg of Gd-EOB-DTPA. The healthy volunteers underwent an additional examination using 0.05 mmol/kg of Gd-BOPTA. The signal intensities (SI) of liver and spleen parenchyma were obtained from unenhanced and enhanced acquisitions. Using pharmacokinetic models of the liver and spleen, and an SI rescaling procedure, a hepatic uptake rate, K (Hep), estimate was derived. The K (Hep) values for Gd-EOB-DTPA were then studied in relation to those for Gd-BOPTA and to a clinical classification of the patient's hepatobiliary dysfunction.

Results: K (Hep) estimated using Gd-EOB-DTPA showed a significant Pearson correlation with K (Hep) estimated using Gd-BOPTA (r = 0.64; P < 0.05) in healthy subjects. Patients with impaired hepatobiliary function had significantly lower K (Hep) than patients with normal hepatobiliary function (K (Hep) = 0.09 ± 0.05 min(-1) versus K (Hep) = 0.24 ± 0.10 min(-1); P < 0.01).

Conclusions: A new procedure for quantifying the hepatocyte-specific uptake of T (1)-enhancing contrast agent was demonstrated and used to show that impaired hepatobiliary function severely influences the hepatic uptake of Gd-EOB-DTPA.

Key Points: • The liver uptake of contrast agents may be measured with standard clinical MRI. • Calculation of liver contrast agent uptake is improved by considering splenic uptake. • Liver function affects the uptake of the liver-specific contrast agent Gd-EOB-DTPA. • Hepatic uptake of two contrast agents (Gd-EOB-DTPA, Gd-BOPTA) is correlated in healthy individuals. • This method can be useful for determining liver function, e.g. before hepatic surgery.

Citing Articles

Assessment of hepatic transporter function in rats using dynamic gadoxetate-enhanced MRI: a reproducibility study.

Gunwhy E, Hines C, Green C, Laitinen I, Tadimalla S, Hockings P MAGMA. 2024; 37(4):697-708.

PMID: 39105950 PMC: 11417070. DOI: 10.1007/s10334-024-01192-5.


Liver metastases: The role of magnetic resonance imaging.

Maino C, Vernuccio F, Cannella R, Cortese F, Franco P, Gaetani C World J Gastroenterol. 2023; 29(36):5180-5197.

PMID: 37901445 PMC: 10600959. DOI: 10.3748/wjg.v29.i36.5180.


Mathematical models for biomarker calculation of drug-induced liver injury in humans and experimental models based on gadoxetate enhanced magnetic resonance imaging.

Karlsson M, Simonsson C, Dahlstrom N, Cedersund G, Lundberg P PLoS One. 2023; 18(1):e0279168.

PMID: 36608050 PMC: 9821424. DOI: 10.1371/journal.pone.0279168.


Liver-spleen contrast standardization of gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced magnetic resonance imaging based on cross-calibration.

Mori H, Akimoto S Quant Imaging Med Surg. 2022; 12(12):5343-5357.

PMID: 36465824 PMC: 9703119. DOI: 10.21037/qims-22-174.


Gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced magnetic resonance imaging for evaluating fibrosis regression in chronic hepatitis C patients after direct-acting antiviral.

Li X, Huang R, Yang M, Wang J, Gao Y, Jin Q World J Gastroenterol. 2022; 28(20):2214-2226.

PMID: 35721884 PMC: 9157620. DOI: 10.3748/wjg.v28.i20.2214.


References
1.
Warntjes J, Dahlqvist Leinhard O, West J, Lundberg P . Rapid magnetic resonance quantification on the brain: Optimization for clinical usage. Magn Reson Med. 2008; 60(2):320-9. DOI: 10.1002/mrm.21635. View

2.
de Bazelaire C, Duhamel G, Rofsky N, Alsop D . MR imaging relaxation times of abdominal and pelvic tissues measured in vivo at 3.0 T: preliminary results. Radiology. 2004; 230(3):652-9. DOI: 10.1148/radiol.2303021331. View

3.
Kamath P, Wiesner R, Malinchoc M, Kremers W, Therneau T, Kosberg C . A model to predict survival in patients with end-stage liver disease. Hepatology. 2001; 33(2):464-70. DOI: 10.1053/jhep.2001.22172. View

4.
Motosugi U, Ichikawa T, Tominaga L, Sou H, Sano K, Ichikawa S . Delay before the hepatocyte phase of Gd-EOB-DTPA-enhanced MR imaging: is it possible to shorten the examination time?. Eur Radiol. 2009; 19(11):2623-9. DOI: 10.1007/s00330-009-1467-6. View

5.
Tsuda N, Okada M, Murakami T . New proposal for the staging of nonalcoholic steatohepatitis: evaluation of liver fibrosis on Gd-EOB-DTPA-enhanced MRI. Eur J Radiol. 2008; 73(1):137-42. DOI: 10.1016/j.ejrad.2008.09.036. View